BSX vs PODD: fair value comparison
Boston Scientific Corporation and Insulet Corporation · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, PODD currently sits closer to the top of our discount ranking.
| BSX | PODD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $47.80 | $147.48 |
| 12-month range | $46.73–$101.01 | $148.13–$318.77 |
| Sector rank | #9 of 113 Healthcare | #4 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | B | — |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: BSX fair value analysis · PODD fair value analysis